Compare Citius Pharmaceuticals Inc (CTXR) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JetBlue Airways Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while JetBlue Airways Corporation trades at $5.82 (market cap $2.19B). The key difference: JetBlue Airways Corporation is far larger — about 109.4× Citius Pharmaceuticals Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | JBLU | |
|---|---|---|
Market Cap | $20.01M | $2.19B |
Sector | Health | Industrials |
52-Week High | $1.82 | $6.46 |
52-Week Low | $0.48 | $4.03 |
Enterprise Value | $16.23M | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
JetBlue (JBLU) trades at $5.64, down 7.08% amid a recent analyst downgrade. The stock shows a bullish technical signal with oversold RSI conditions, but fundamentals reveal persistent losses with a -9.32% net margin and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations, yet revenue trends remain volatile, and cash flow from operations turned negative in 2025. The company is implementing strategic fare changes and targeting 2028 profitability.
The outlook is cautious; while cost initiatives and premium product expansions offer long-term potential, high debt levels, fuel cost pressures, and inconsistent earnings pose significant risks. Analyst consensus is mixed with a hold-heavy rating and a $5.18 price target slightly below the current price, reflecting skepticism about near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
